Načítá se...

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been imp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Bhatti, Maria, Ippolito, Thomas, Mavis, Cory, Gu, Juan, Cairo, Mitchell S., Lim, Megan S., Hernandez-Ilizaliturri, Francisco, Barth, Matthew J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955151/
https://ncbi.nlm.nih.gov/pubmed/29774105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!